Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
William John Scheessele is Chief Commercial Officer at Humacyte. OQRO lists 1 transaction filed with the SEC under this name, the latest on Apr 15, 2025, each linked to the official Form 4.
Chief Commercial Officer
Disclosures on record
1
Companies involved
1
1 buy, median +28.8 pts vs S&P 500, beat it 1 of 1 time.
Average +28.8 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Apr 15, 2025 to Apr 15, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 100% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
HumacyteHUMA
Apr 14, 2025Bought~$10Kdisclosed Apr 15
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
As of the latest filing on , William John Scheessele reported holding 22,018 shares of Humacyte (HUMA), worth about $12K at the last close of $1 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Humacyte HUMA | 22,018 | 22K direct | $1 | $12K | Apr 14, 2025 |
Is this William John Scheessele’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
William John Scheessele bought shares on the open market in 2022 and 2025.
William John Scheessele reported 3 open-market purchases and 0 sales since 2022; purchases in 2 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $10K1×1 trade | — |
| 2022 | $65K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Apr 14, 2025, William John Scheessele reported holding 22,018 shares of Humacyte (HUMA). At the last close of $1 on Nov 13, 2026, that is about $12K. This is the stake disclosed in filings, not a net worth.
William John Scheessele bought shares on the open market in 2022 and 2025.
In SEC filings since 2022: the latest open-market purchase is from 2025; no open-market sale is on record.
Humacyte (HUMA), from 2022 to 2025: 3 purchases and 0 sales.
William John Scheessele reported 3 open-market purchases and 0 sales here, 2022 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.